Cervical carcinoma is the second most frequent cancer type in women worldwide. Both inflammatory cells and stromal cells are important for tumor progression. Stromal cells produce growth factors and extracellular matrix and provide an adequate environment for angiogenesis. Versican, a member of the extracellular matrix, has been shown to have a role in tumor progression. The aim of this study was to investigate versican expression, and its association with tumor-infiltrating inflammatory cell subsets and with clinicopathological parameters in human cervical cancers. We have studied the expression of versican in 149 cervical cancers using immunohistochemistry and mRNA in situ hybridization. Versican was predominantly expressed in the stroma (myofibroblasts). Using quantitative real-time-PCR, V0 was found to be the most prominent isoform. High stromal versican expression was significantly associated with a low number of tumor-infiltrating T cells (P ¼ 0.018) and particularly a low number of CD8-positive T cells (cytotoxic T cells; P ¼ 0.002). Stromal versican expression was significantly higher in patients with an infiltration depth 414 mm (P ¼ 0.004) and in patients with parametrial invasion (P ¼ 0.044). Stromal versican expression was not associated with survival. Our results suggest that versican expression in the stromal compartment of cervical cancers results in reduced numbers of intraepithelial CD8-positive T cells and enhanced local invasion.
Cervical carcinoma is the second most common cancer type in women worldwide. 1 It is caused by a persistent infection with high-risk human papillomavirus (HPV) types. Next to malignant epithelial cells, this tumor consists of inflammatory cells and stromal cells. Both inflammatory and stromal cells are important for tumor progression. 2, 3 In cervical carcinoma there is a high amount of inflammatory infiltrate, and we have recently shown a correlation between a high number of intraepithelial regulatory T cells (Treg) and poor survival of cervical carcinoma patients. 4 Stromal cells produce growth factors and extracellular matrix (ECM) components and provide an adequate environment for angiogenesis.
One of these ECM components is versican, which is a member of the large aggregating chondroitin sulfate proteoglycan (CSPG) family that has been implicated in tumor progression. 5 Versican is composed of a N-terminal globular G1 domain, a central glycosaminoglycan attachment region (GAG) and a C-terminal selectin-like G3 domain. 6 Four isoforms are generated by alternative splicing: V0 containing both GAGa and GAGb domains, V1 containing the GAGa domain, V2 containing the GAGb domain and V3 consisting only of the globular domains. 7 Recently, a fourth isoform, V4, has been found in breast cancer. 8 The different isoforms are implicated in different biological processes. The V0 isoform is highly expressed during embryonic development, 9 whereas in adult human tissues the V1 isoform is most prevalent.
10 V0 and V1 are also the predominant isoforms found in cancer tissue. [11] [12] [13] [14] Versican expression promotes tumor growth by destabilizing focal cell contacts, thus hampering cell adhesion and regulating angiogenesis. 10, 15 Indeed, increased levels of versican have been reported in different tumor types such as adenocarcinomas, [16] [17] [18] squamous cell carcinomas, 19, 20 sarcomas, 21 mesotheliomas 22 and malignant melanomas. 23 In addition, versican expression has been associated with tumor progression and decreased survival in various tumor types. [24] [25] [26] In cervical cancer, versican has been suggested to enhance tumor invasion and metastases formation. 20 In this study, we have investigated the presence, isotype and location of versican in cervical carcinoma. We have determined the association between the presence of versican and the presence of different tumor-infiltrating inflammatory cell subsets. In addition, we have investigated the association of versican with several clinicopathological parameters such as lymph node positivity and diseasefree and overall survival.
Materials and methods

Tissue Samples
A total of 149 patients treated with radical hysterectomy and bilateral pelvic lymph node dissection for uterine cervical cancer were included in this study. Patients did not receive preoperative radiotherapy or chemotherapy. Treatment occurred between 1985 and 1999. Tissues had been fixed routinely in 10% formalin and embedded in paraffin. All tissues were retrieved from the archives of the Department of Pathology, Leiden University Medical Center. Samples were used according to the guidelines of the ethical committee of the Leiden University Medical Center. Clinical parameters were stored in a prospective database (administered by the Department of Gynecology) containing over 200 items per patient. The patient characteristics are shown in Table 1 .
Immunohistochemistry
Immunohistochemical analysis was performed on 4 mm paraffin sections, mounted on aminopropylethoxysilane-coated slides. Sections were deparaffinized, rehydrated and treated with 0.3% H 2 O 2 in methanol for 20 min to block endogenous peroxidase activity. Antigen retrieval was performed (0.01 M citrate, pH 6.0) and sections were rinsed in phosphate-buffered saline (PBS). Subsequently, sections were stained for versican (overnight) using a 1:200 dilution of anti-human versican monoclonal antibody (clone 2B1, IgG1; Seikagaku Corporation, Tokyo, Japan) in PBS containing 1% bovine serum albumin (BSA). The slides were next incubated with Powervision-Poly-HRP-goat anti-mouse/rat/rabbit IgG (Immunogenic, Duiven, The Netherlands) and immune complexes were visualized with diaminobenzidine. CD68-positive cells, CD1a (Langerhans cells)-positive intraepithelial cells or DC-LAMPpositive stromal dendritic cells were visualized as described previously. The primary antibodies were diluted in PBS/ 2% BSA in one mixture. The slides were incubated overnight with this mixture (100 ml per sample). The next day, the slides were washed with PBS. The slides were then incubated for 1 h with the secondary antibodies (100 ml per sample; goat-anti-mouse IgG2a ALEXA 546 (red), 1:200; goat-anti-mouse IgG1 ALEXA 488 (green), 1:200; and goat-anti-mouse IgG2b ALEXA 647 (blue), 1:200). All ALEXA antibodies were obtained from Invitrogen (Invitrogen, Breda, The Netherlands). After this, the slides were washed with PBS and then mounted with MOWIOL.
mRNA In Situ Hybridization
Primers were chosen on the basis of the versican mRNA sequence (GenBank accession number GI_28144902): 5 0 -CAAGCATCCTGTCTCACGAA-3 0 (sense) and 5 0 -TTGGTATGCAGATGGGTTCA-3 0 (antisense). Probes were prepared and cervical carcinoma sections were stained for versican mRNA as previously described. 28 In short, 3 mm paraffin sections were pre-treated and hybridized with 100 ng/ml digoxigenin-labeled mRNA probe diluted in hybridization mixture containing 0.3 M NaCl and 0.03 M saline sodium citrate (SSC). Hybridization was allowed for 16 h at 55 1C in a humidified chamber. Slides were washed for 30 min in 50% formamide/ 2 Â SSC at 42 1C, followed by 45 min in 0.1 Â SSC with 20 mM b-mercaptoethanol at 50 1C and for 30 min with 2 U/ml ribonuclease T1 (Roche Diagnostics GmbH, Mannheim, Germany) in 2 Â SSC, 1 mM EDTA at 37 1C. RNA hybrids were detected using subsequently mouse anti-digoxigenin (1:2000; SigmaAldrich Chemie GmbH, Steinham, Germany), rabbit anti-mouse immunoglobulin (1:50; DAKO, Glostrup, Denmark) and mouse alkaline phosphatase antialkaline phosphatase (DAKO, Glostrup, Denmark). A cervical cancer sample stained for TGF-b1 mRNA served as a positive control.
Evaluation of Immunohistochemical Staining and mRNA In Situ Hybridization
Versican expression was scored as described by Ruiter et al. 29 Intensity was scored as none (0), mild (1), moderate (2) or intense (3) at low magnification ( Â 100). Furthermore, the percentage of positive tumor cells was determined and divided into groups: 0% (0, absent), 1-5% (1, sporadic), 6-25% (2, local), 26-50% (3, occasional), 51-75% (4, majority) and 76-100% (5, large majority). The two parameters were combined, representing the sum of both the percentage and the staining intensity of the positive cells, which resulted in an overall score (0 or 2-8). The scores were combined into two groups: category 0 (score 0-5, low expression) and category 1 (score 6-8, high expression). Expression was scored by two independent researchers without knowing the identity and clinical outcome of patients. The data on T-cell infiltration in this patient series were previously published. 4 
Quantitative Real-Time-PCR (qRT-PCR)
In all, 2 mg of total RNA was transcribed to cDNA with Superscript II reverse transcriptase (Life Technologies, Grand Island, NY, USA). Amplification reactions were performed with qPCR Core kit for SYBR Green (Eurogentec, Hampshire, UK) according to the manufacturer's protocol. Fluorescent PCR analysis was performed using the BIO-RAD iCycler (BIO-RAD, Hercules, CA, USA). The following PCR conditions were used: 10 min at 95 1C, followed by 45 cycles of 15 s at 95 1C and 1 min at the appropriate annealing temperature. The household gene EEF1A1 was used for normalization of the expression data. 30 Primers were designed according to Zhao et al. 31 Relative quantification was performed using standard curves, followed by adjustment with the normalization factor, which was calculated using the Genorm program. The primer sequences are listed in Table 2 .
Statistical Analysis
Statistical analysis was performed using SPSS 16.0 (SPSS, Chicago, IL, USA). Data were processed using the w 2 test, Student's t-test, the Mann-Whitney U-test or the Fisher's exact test, depending on the number and distribution of the compared groups. The Po0.05 was considered statistically significant.
Results
Versican Is Predominantly Expressed in the Stroma
First, we investigated the presence and location of versican in 149 cervical cancer specimens using 
Versican in cervical carcinoma
A Gorter et al immunohistochemistry. Versican expression was predominantly observed in the stroma (Figure 1a-d) .
The expression of versican showed a heterogeneous staining pattern and was more pronounced at the invasive border in 127 out of 142 cervical cancer specimens. In 62 out of 149 specimens, Figure 1 The expression and location of versican. The expression and location of versican was determined using immunohistochemistry as well as RNA-in situ hybridization as described in the Materials and methods ( Â 250 magnification). 
versican expression was also found in the cervical carcinoma cells (Figure 1d, arrow) . Tumors without versican expression were not observed. To quantify the versican expression, the scoring system of Ruiter et al 29 was used. Weak immunoreactivity (score 2-5) was observed in 93 cases, and strong immunoreactivity (score 6-8) was observed in 56 cases. As a control, the versican expression was determined in normal cervical tissue (Figure 1e ). In this case, moderate expression of versican was found in the subepithelial tissue. As strong expression was found at the stromal-epithelial border, we determined whether tumor cell or (myo)fibroblast were associated with versican expression (Figure 2 ). For this purpose, immunofluorescent double staining with both anti-cytokeratin (tumor cells) and anti-SMA (myofibroblasts) and versican was performed. None of the tumor cells expressed in addition to keratin SMA (Figure 2a ). The majority of versican expression was associated with myofibroblasts and only a few versican-positive tumor cells were identified (Figure 2b ). Strong versican expression was observed around blood vessels in the tumor stroma.
To determine whether the tumor or the stromal cells in cervical carcinomas produce versican, mRNA in situ hybridization was performed using placental tissue as a positive control. Placental tissue, strongly positive according to the qRT-PCR results, showed a weak staining at the tip of the villi. Only a weak expression of versican was detected in the cervical cancer tissue. The expression of versican in cervical cancer tissue was predominantly present in the stromal compartment (Figure 1f ).
The V0 Isoform Is Preferentially Expressed in Cervical Cancer
Because versican can be expressed in different isoforms (V0, V1, V2 and V3), their expression was measured using qRT-PCR in 8 cervical cancer cell lines and 20 cervical carcinoma samples. Normal lung and placenta tissue served as a positive control. The expression level of each isoform was normalized to the household gene EEF1A1. From the cell lines investigated, CC10B expressed V0, V1 and V2, CSCC7 expressed V1 and HeLa expressed V3. CaSki, CSCC1, CC8, CC11 and SiHa did not express versican. To verify the mRNA expression pattern, versican protein expression was determined on cytospin preparations from CC10B and Caski. As expected, only CC10B showed prominent versican expression (data not shown). Previously, we have performed a cDNA microarray analysis on 32 tumor specimens. 32 All the cervical cancer samples examined in that study expressed versican (data not shown). In the present study, we have investigated the versican isoforms expressed in 20 tumor samples. V0 was found to be the most prominent isoform (Figure 3 ).
High Versican Expression Is Associated with a Decreased Number of Intraepithelial CD8-Positive T Cells
As the composition of the ECM influences the migration of inflammatory cells, 33 we have also measured the association between inflammatory 
Versican Expression Is Correlated with Infiltration Depth
As an association was found between high numbers of CD8-positive T cells and limited expression of versican, we determined whether this was also reflected in an association with clinical parameters. We have associated high or low versican expression with FIGO stage, lymph node metastasis, tumor size, infiltration depth, vascular space involvement, parametrial invasion, HPV status and histology (Table 1) . Tumors with high versican expression were significantly associated with an infiltration depth of Z15 mm (P ¼ 0.004) and parametrial invasion (P ¼ 0.044). However, no statistically significant association between patients with tumors with high versican expression and patient survival was observed.
Discussion
In this study, we have investigated the expression of versican in cervical cancer and have correlated its expression with the presence of inflammatory cells and clinicopathological parameters. As observed by Kodama et al, 20 versican is predominantly expressed in the stromal compartment, although occasionally tumor cells are also positive. As previously shown for breast tumors, in cervical tumors also intense versican staining was observed in the peripheral area of the tumors. 34 Using immunofluorescent Figure 3 The expression of versican isoforms in cervical cancer. Isoform expression was measured with qRT-PCR in 20 cervical specimens as described in the Materials and methods. Versican expression was normalized against a household gene (EEF1A1). 8, [11] [12] [13] [14] The V1 isoform has been shown to enhance cell proliferation and to protect fibroblasts from apoptosis. 35 Increased levels of versican have been found in brain tumors, cervical carcinomas, melanomas, breast cancer, prostate cancer, colorectal cancer, lung cancer, pancreatic cancer, endometrial cancer, oral cancer and ovarian cancer. 12, 13, [16] [17] [18] 20, 23, 34, [36] [37] [38] [39] As the composition of the ECM influences the migration of inflammatory cells, 33 we have also measured the association between inflammatory cells and versican expression. Despite the reported production of versican isoforms V0 and V1 by human leukemic monocytes 40 and the reported 
Versican in cervical carcinoma
A Gorter et al increased synthesis of versican by hypoxic macrophages, no significant statistical association was observed for stromal or intraepithelial CD68-positive cells in our study. Recently, in a rat experimental model, fragments of versican were shown to activate TLR2-positive macrophages. 41 We could demonstrate TLR2-positive macrophages in both the stroma and within the epithelial compartment (data not shown); however, no statistically significant association between versican expression and the presence of TLR2-positive macrophages was observed. In addition, we did not find an association between TLR2-positive macrophages and TNFa expression (data not shown). However, a statistically significant correlation between tumors with a low number of intraepithelial T cells and tumors with high versican expression was shown. Versican is known to bind several cytokines and chemokines, such as XCL1 (Lymphotactin), CCL5 (RANTES), CCL20 (LARC) and CCL21 (SLC), all of which are potent T-cell chemoattractants. 42 It is noteworthy that CCL5 expression has been associated with CD8-positive T-cell infiltration 43 and that mouse 6Ckine (CCL21 in humans) when transfected into a colon carcinoma cell line has both antitumor activity mediated by CD8-positive T cells and angiostatic effects. 44 This suggests that versican might act as a molecular sink, trapping CCL5 and CCL21, and offers We also have associated the expression of versican with relevant clinical parameters such as lymph node metastasis, tumor size, infiltration depth and vascular space involvement. Although for breast, cervical, prostate and other tumor types, increased versican expression has been associated with relapse and poor clinical outcome, 12, 16, 17, 19, 20, 36, 39, 45, 46 we could not demonstrate this association in our cervical cancer cohort. To exclude that this was related to the scoring system, we have also scored our data according to the method described by Kodama et al 20 (data not shown), but in this case also no statistically significant association was found. However, we did find a statistically significant association with an infiltration depth of Z15 mm (P ¼ 0.004). As there is a significant association between infiltration depth and survival, we stratified infiltration depth according to versican expression. The results show that (low or high) versican expression does not affect survival of cervical cancer patients with an infiltration depth of o15 mm, whereas in cervical cancer patients with infiltration depth of Z15 mm, low versican expression predicts a poorer survival. However, because of the limited number of cases (n ¼ 60), the survival difference between patients with a low versican or a high versican expression in this subgroup of cervical cancer patients was not significant (data not shown).
In the studies of Kodama et al, 20, 45 the depth of stromal invasion (cervical cancer) and myometrial invasion (endometrial cancer) was also associated with versican expression, although in both studies only a trend (P ¼ 0.069 and P ¼ 0.052, respectively) was observed. However, experimental support for a role of versican in invasion was provided by functional studies demonstrating that versican is able to increase cancer cell motility 47 and to reduce the attachment of cancer cells to fibronectin-coated surfaces. 48 In conclusion, our results suggest that modulation of the ECM composition in the peripheral stromal area of cervical cancers influences the migration of cytotoxic T cells and enhances local invasion of the tumor cells. Figure 5 Association between versican expression and intraepithelial CD8-positive T cells. Versican and CD8 expression were determined using (fluorescent) immunohistochemistry as described in the Materials and methods. Immunohistochemical versican scores were combined into two groups: low versican expression (score 0-5) and high versican expression (score 6-8), as described in the Materials and methods. CD8-positive T cells were quantified as described in the Materials and methods and expressed as number per mm 2 .
